NSCLC (Non-small Cell Lung Cancer) Clinical Trials

24 recruiting

NSCLC (Non-small Cell Lung Cancer) Trials at a Glance

24 actively recruiting trials for nsclc (non-small cell lung cancer) are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 9 trials, with the heaviest enrollment activity in Fairfax, Houston, and Chicago. Lead sponsors running nsclc (non-small cell lung cancer) studies include Tianjin Medical University Cancer Institute and Hospital, Elephas, and Alterome Therapeutics, Inc..

Browse nsclc (non-small cell lung cancer) trials by phase

Treatments under study

About NSCLC (Non-small Cell Lung Cancer) Clinical Trials

Looking for clinical trials for NSCLC (Non-small Cell Lung Cancer)? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NSCLC (Non-small Cell Lung Cancer) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NSCLC (Non-small Cell Lung Cancer) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Locally Advanced or Metastatic Solid TumorsNSCLC (Non-small Cell Lung Cancer)Esophageal Squamous Cell Cancer+1 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 2

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital20 enrolled1 locationNCT07528274
Recruiting
Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

CancerAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc.188 enrolled10 locationsNCT06835569
Recruiting
Phase 1Phase 2

Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)

NSCLC (Non-small Cell Lung Cancer)
Tang-Du Hospital20 enrolled1 locationNCT07354061
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NSCLC (Non-small Cell Lung Cancer)
Revolution Medicines, Inc.420 enrolled129 locationsNCT06881784
Recruiting
Not Applicable

Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

NSCLC (Non-small Cell Lung Cancer)
Tau Medical Australia Pty Ltd7 enrolled1 locationNCT07122258
Recruiting
Phase 1

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Advanced Solid TumorMesotheliomaRenal Cancer+3 more
Nuvectis Pharma, Inc.140 enrolled12 locationsNCT05873686
Recruiting

Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup

NSCLC (Non-small Cell Lung Cancer)Oligometastatic Lung TumorSBRT
Institut du Cancer de Montpellier - Val d'Aurelle190 enrolled2 locationsNCT07441941
Recruiting
Phase 1Phase 2

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

LymphomaNSCLC (Non-small Cell Lung Cancer)Solid Advanced Tumor
OSE Immunotherapeutics41 enrolled11 locationsNCT05751798
Recruiting
Phase 1

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

Melanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)CRC (Colorectal Cancer)+1 more
Hefei TG ImmunoPharma Co., Ltd.194 enrolled1 locationNCT07376707
Recruiting
Phase 2

Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)

MRDNSCLC (Non-small Cell Lung Cancer)II-IIIB Stages+1 more
Guangdong Association of Clinical Trials115 enrolled2 locationsNCT07120698
Recruiting
Phase 2

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital31 enrolled1 locationNCT07330050
Recruiting

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

NSCLC (Non-small Cell Lung Cancer)Metastatic NSCLC - Non-Small Cell Lung Cancer
Elephas200 enrolled7 locationsNCT05478538
Recruiting
Phase 1

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

Endometrial CancerCholangiocarcinomaMelanoma+5 more
West China Hospital10 enrolled1 locationNCT07106827
Recruiting
Phase 1Phase 2

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Solid TumorNSCLC (Non-small Cell Lung Cancer)
Yuhan Corporation161 enrolled8 locationsNCT06616766
Recruiting

Pan-tumor MRD Study

Esophageal CancerMelanoma (Skin Cancer)NSCLC (Non-small Cell Lung Cancer)+4 more
Paradigm Health1,350 enrolled2 locationsNCT06605404
Recruiting
Phase 3

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

NSCLC (Non-small Cell Lung Cancer)
Guangdong Provincial People's Hospital70 enrolled1 locationNCT07016126
Recruiting

Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC Patients

NSCLC (Non-small Cell Lung Cancer)
Medical University of Vienna90 enrolled1 locationNCT06967532
Recruiting
Phase 2

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital38 enrolled1 locationNCT06939127